Androgen Receptor Status Is a Prognostic Marker in Non-Basal Triple Negative Breast Cancers and Determines Novel Therapeutic Options

Triple negative breast cancers are a heterogeneous group of tumors characterized by poor patient survival and lack of targeted therapeutics. Androgen receptor has been associated with triple negative breast cancer pathogenesis, but its role in the different subtypes has not been clearly defined. We examined androgen receptor protein expression by immunohistochemical analysis in 678 breast cancers, including 396 triple negative cancers. Fifty matched lymph node metastases were also examined. Association of expression status with clinical (race, survival) and pathological (basal, non-basal subtype, stage, grade) features was also evaluated. In 160 triple negative breast cancers, mRNA microarray expression profiling was performed, and differences according to androgen receptor status were analyzed. In triple negative cancers the percentage of androgen receptor positive cases was lower (24.8% vs 81.6% of non-triple negative cases), especially in African American women (16.7% vs 25.5% of cancers of white women). No significant difference in androgen receptor expression was observed in primary tumors vs matched metastatic lesions. Positive androgen receptor immunoreactivity was inversely correlated with tumor grade (p<0.01) and associated with better overall patient survival (p = 0.032) in the non-basal triple negative cancer group. In the microarray study, expression of three genes (HER4, TNFSF10, CDK6) showed significant deregulation in association with androgen receptor status; eg CDK6, a novel therapeutic target in triple negative cancers, showed significantly higher expression level in androgen receptor negative cases (p<0.01). These findings confirm the prognostic impact of androgen receptor expression in non-basal triple negative breast cancers, and suggest targeting of new androgen receptor-related molecular pathways in patients with these cancers.

[1]  Aleix Prat Aparicio.  Comprehensive molecular portraits of human breast tumours , 2012 .

[2]  Yan Peng,et al.  Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. , 2012, American journal of clinical pathology.

[3]  H. Park,et al.  Expression of androgen receptors in primary breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Paul E Swanson,et al.  Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. , 2003, American journal of clinical pathology.

[5]  Harvard Medical School,et al.  Targeting androgen receptor in estrogen receptor-negative breast cancer. , 2011, Cancer cell.

[6]  S. Clark,et al.  Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events , 2012, BMC Cancer.

[7]  Qingyuan Zhang,et al.  The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer , 2012, Medical Oncology.

[8]  A. León,et al.  Androgens and androgen receptors in breast cancer , 2007, Journal of Steroid Biochemistry and Molecular Biology.

[9]  B. Franco.  Androgens and breast cancer. , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[10]  Takashi Suzuki,et al.  Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation , 2013, Cancer science.

[11]  L. Tanoue,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[12]  Funda Meric-Bernstam,et al.  Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes , 2013, Clinical Cancer Research.

[13]  C. Morrison,et al.  Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features , 2011, Breast Cancer Research and Treatment.

[14]  C. Croce,et al.  Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer , 2013, PloS one.

[15]  Takashi Suzuki,et al.  Androgen receptor in triple negative breast cancer , 2013, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  W. Koch,et al.  CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy , 2012, Cell cycle.

[17]  W. Gerald,et al.  An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen , 2006, Oncogene.

[18]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[19]  T. H. van der Kwast,et al.  The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. , 1996, European journal of cancer.

[20]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[21]  D. Horsfall,et al.  Androgens induce divergent proliferative responses in human breast cancer cell lines , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  Zhongyu Yuan,et al.  Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray , 2012, Medical Oncology.

[23]  B. Anderson,et al.  Androgens and androgen receptors: A clinically neglected sector in breast cancer biology , 2007, Journal of surgical oncology.

[24]  T. Barrette,et al.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.

[25]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[26]  S. Yeh,et al.  Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver , 2014, Oncogene.

[27]  Rohit Bhargava,et al.  Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation , 2010, Modern Pathology.

[28]  J. Carroll,et al.  Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? , 2012, Molecular endocrinology.

[29]  A. Levine,et al.  Attenuation of the Retinoblastoma Pathway in Pancreatic Neuroendocrine Tumors Due to Increased Cdk4/Cdk6 , 2012, Clinical Cancer Research.

[30]  Puay Hoon Tan,et al.  Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer , 2014, Modern Pathology.

[31]  E. Winer,et al.  Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network , 2012, Cancer.

[32]  A. Luini,et al.  Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. , 2013, Clinical breast cancer.

[33]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[34]  L. Butler,et al.  Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors , 2012, Cell cycle.

[35]  A. Becker,et al.  Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. , 2013, Journal of medicinal chemistry.

[36]  K. Lee,et al.  Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  C. Hudis,et al.  Triple-negative breast cancer: an unmet medical need. , 2011, The oncologist.

[38]  W. Gerald,et al.  Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer , 2009, Clinical Cancer Research.

[39]  E. Knudsen,et al.  Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition , 2012, The Journal of Biological Chemistry.

[40]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[41]  A. Wolff,et al.  The androgen receptor in breast cancer: learning from the past , 2010, Breast Cancer Research and Treatment.

[42]  H. Cunliffe,et al.  Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype , 2014, Annals of Surgical Oncology.

[43]  G. Secreto,et al.  Role of androgen excess in the development of estrogen receptor-positive and estrogen receptor-negative breast cancer. , 2012, Anticancer research.

[44]  D. Rakheja,et al.  Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma. , 2010, American journal of clinical pathology.

[45]  A. Schneeweiss,et al.  Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. , 2013, Breast.

[46]  S. Yeh,et al.  Abnormal Mammary Gland Development and Growth Retardation in Female Mice and MCF7 Breast Cancer Cells Lacking Androgen Receptor , 2003, The Journal of experimental medicine.

[47]  Z. Nahleh.  Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. , 2008, Future oncology.

[48]  T. Traina,et al.  Triple-Negative Breast Cancer: Role of the Androgen Receptor , 2010, Cancer journal.

[49]  S. Volinia,et al.  Fragile histidine triad protein, WW domain‐containing oxidoreductase protein Wwox, and activator protein 2γ expression levels correlate with basal phenotype in breast cancer , 2009, Cancer.